Ascletis to Present Breakthrough Data on ASC30 at EASD
Ascletis Pharma Inc. is poised to share significant findings from its Phase Ib clinical research concerning the oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30. The presentation will feature results from a 28-day multiple ascending dose study, which aims to provide insights into the medication's effectiveness in managing obesity.
What Does the Study Involve?
The focus of this innovative study is to investigate the safety and efficacy of the ASC30 oral tablet among participants struggling with obesity or overweight conditions. The upcoming oral discussion at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting promises to shine a spotlight on dramatic findings that may reshape obesity treatment methodologies.
Abstract Highlights
The abstract titled "ASC30, an oral GLP-1R biased small molecule agonist demonstrated superior weight loss in participants with obesity: a 28-day multiple ascending dose study" emphasizes the potential of ASC30. This session is categorized under Short Oral Discussion Sessions Event A: SO 073, highlighting diverse GLP-1 formulations.
Presentation Timeline
Scheduled for September 16, 2025, from 12:00 to 13:00 CEST, this key presentation will occupy a distinctive slot as presentation number 827. The findings are highly anticipated within the medical community.
Why This Matters
As explained by Jinzi Jason Wu, Ph.D., the Founder, Chairman, and CEO of Ascletis, there is immense excitement regarding the potential implications this data could have on treatment options for obesity. With a goal of positioning ASC30 as a leading alternative in this area, Ascletis underscores the importance of these findings for both patients and healthcare providers.
Understanding ASC30
ASC30 stands out as an investigational GLP-1R biased small molecule agonist. Its unique properties allow for two administration approaches: as an oral tablet and via subcutaneous injection. This flexibility could broaden treatment options for those battling weight issues. Notably, ASC30 represents a new chemical entity (NCE) and is protected under global patents until 2044.
The Role of EASD
The European Association for the Study of Diabetes (EASD), founded in 1965, plays a vital role in advancing diabetes research. With an extensive program designed to facilitate knowledge transfer and application, the EASD Annual Meeting is renowned for its emphasis on groundbreaking research and expert discussions, such as those surrounding ASC30.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. operates as a fully integrated biotechnology firm concentrating on cutting-edge therapeutics for metabolic diseases. Utilizing a combination of Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and an Ultra-Long-Acting Platform (ULAP), the company has developed multiple innovative drug candidates. Leading the charge is ASC30, a promising GLP-1R agonist under development for both daily oral use and less frequent subcutaneous injections, offering convenience in weight management.
Frequently Asked Questions
What is ASC30?
ASC30 is an investigational oral GLP-1 receptor agonist designed to aid in weight management.
What were the results from the 28-day study?
The study showed promising safety and efficacy results which will be disclosed at the EASD Annual Meeting.
When is the EASD Annual Meeting?
The annual meeting is scheduled for September 15-19, 2025, in Vienna.
How does ASC30 differ from other treatments?
ASC30 can be administered as both a tablet and an injection, which differentiates it from many existing options.
What are the future plans for ASC30?
Ascletis plans to report topline data from a Phase IIa clinical study in the fourth quarter of 2025, looking to further validate ASC30's potential.
